JP7457642B2 - タンパク質抗原およびその使用 - Google Patents

タンパク質抗原およびその使用 Download PDF

Info

Publication number
JP7457642B2
JP7457642B2 JP2020502551A JP2020502551A JP7457642B2 JP 7457642 B2 JP7457642 B2 JP 7457642B2 JP 2020502551 A JP2020502551 A JP 2020502551A JP 2020502551 A JP2020502551 A JP 2020502551A JP 7457642 B2 JP7457642 B2 JP 7457642B2
Authority
JP
Japan
Prior art keywords
peptide
cell
cells
cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515640A (ja
JP2020515640A5 (enExample
Inventor
マイケル スティーブン ルーニー，
Original Assignee
ビオンテック ユーエス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビオンテック ユーエス インコーポレイテッド filed Critical ビオンテック ユーエス インコーポレイテッド
Publication of JP2020515640A publication Critical patent/JP2020515640A/ja
Publication of JP2020515640A5 publication Critical patent/JP2020515640A5/ja
Priority to JP2023090878A priority Critical patent/JP2023106599A/ja
Application granted granted Critical
Publication of JP7457642B2 publication Critical patent/JP7457642B2/ja
Priority to JP2025031867A priority patent/JP2025084910A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020502551A 2017-04-03 2018-04-03 タンパク質抗原およびその使用 Active JP7457642B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023090878A JP2023106599A (ja) 2017-04-03 2023-06-01 タンパク質抗原およびその使用
JP2025031867A JP2025084910A (ja) 2017-04-03 2025-02-28 タンパク質抗原およびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762480596P 2017-04-03 2017-04-03
US201762480597P 2017-04-03 2017-04-03
US201762480593P 2017-04-03 2017-04-03
US62/480,596 2017-04-03
US62/480,597 2017-04-03
US62/480,593 2017-04-03
PCT/US2018/025933 WO2018187356A2 (en) 2017-04-03 2018-04-03 Protein antigens and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023090878A Division JP2023106599A (ja) 2017-04-03 2023-06-01 タンパク質抗原およびその使用

Publications (3)

Publication Number Publication Date
JP2020515640A JP2020515640A (ja) 2020-05-28
JP2020515640A5 JP2020515640A5 (enExample) 2021-05-13
JP7457642B2 true JP7457642B2 (ja) 2024-03-28

Family

ID=62063214

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020502551A Active JP7457642B2 (ja) 2017-04-03 2018-04-03 タンパク質抗原およびその使用
JP2023090878A Pending JP2023106599A (ja) 2017-04-03 2023-06-01 タンパク質抗原およびその使用
JP2025031867A Pending JP2025084910A (ja) 2017-04-03 2025-02-28 タンパク質抗原およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023090878A Pending JP2023106599A (ja) 2017-04-03 2023-06-01 タンパク質抗原およびその使用
JP2025031867A Pending JP2025084910A (ja) 2017-04-03 2025-02-28 タンパク質抗原およびその使用

Country Status (6)

Country Link
US (1) US12303561B2 (enExample)
EP (1) EP3606550A2 (enExample)
JP (3) JP7457642B2 (enExample)
CN (2) CN118370809A (enExample)
CA (1) CA3058807A1 (enExample)
WO (1) WO2018187356A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
RS65430B1 (sr) 2016-03-16 2024-05-31 Amal Therapeutics Sa Kombinacija modulatora imunološke kontrolne tačke i kompleksa koji sadrži peptid koji prodire u ćeliju, teret i tlr peptidni agonist za primenu u medicini
KR102879364B1 (ko) 2016-09-21 2025-11-04 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
KR20240149976A (ko) 2017-04-04 2024-10-15 바린투스 바이오테라퓨틱스 노쓰 아메리카, 인크. 펩티드-기반 백신, 그의 제조 방법, 및 면역 반응을 유도하기 위한 그의 용도
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
AU2020282369A1 (en) 2019-05-30 2022-01-20 Seattle Project Corp. Modified adenoviruses
KR20220035457A (ko) * 2019-07-21 2022-03-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 치료 바이러스 백신
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
CN113493494B (zh) * 2020-03-20 2022-08-16 上海交通大学医学院附属瑞金医院 Eb病毒balf3蛋白的抗原表位
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
EP4293038A4 (en) * 2021-02-10 2025-06-18 Xiamen University PEPTIDE EPITOPE AND ANTIBODY FOR PREVENTING AND TREATING EB VIRUS INFECTION AND ASSOCIATED DISEASES
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN114128714B (zh) * 2021-12-07 2023-05-02 昆明学院 一种提高葡萄耐铝毒胁迫的药剂及处理方法
WO2023111306A1 (en) * 2021-12-17 2023-06-22 Evaxion Biotech A/S Personalized cancer therapy targeting normally non-expressed sequences
EP4626903A1 (en) * 2022-12-02 2025-10-08 Seattle Project Corp. Compositions and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544614A (ja) 2006-07-21 2009-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒト内在性レトロウイルスポリペプチド組成物およびその使用法

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
SG52492A1 (en) 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
CA2157510A1 (en) 1993-03-05 1994-09-15 Howard M. Grey Hla-a2.1 binding peptides and their uses
DK0735893T3 (da) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
FR2753627B1 (fr) 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
AU5898400A (en) 1999-06-29 2001-01-31 Epimmune, Inc. Hla binding peptides and their uses
JP2003509035A (ja) * 1999-09-16 2003-03-11 ザイコス インク． ポリエピトープポリペプチドをコードする核酸
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
EP1250351B1 (en) 2000-01-28 2005-11-30 Statens Serum Institut Methods to identify ctl epitopes of hiv
CA2343602A1 (en) 2000-04-18 2001-10-18 Genset Est's and encoded human proteins
BR0111956A (pt) * 2000-06-26 2003-05-13 Stressgen Biotechnologies Corp Tratamento do vìrus do papiloma humano
DE10037759A1 (de) 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
EP1911461B1 (en) * 2000-10-19 2011-12-07 Epimmune Inc. HLA class I and II binding peptides and their uses
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
EP1338606A1 (en) 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
JPWO2003090788A1 (ja) 2002-04-24 2005-08-25 株式会社ギンコバイオメディカル研究所 Ｔｈ２サイトカイン関連アレルギー疾患を治療および／または予防するためのデコイ、ＧＡＴＡ３変異体蛋白質、ならびにこれらを含む医薬組成物
CN1650012A (zh) 2002-07-24 2005-08-03 英特塞尔股份公司 来自致病病毒的备选阅读框所编码的抗原
JP2006503914A (ja) * 2002-10-21 2006-02-02 エムジーアイ ファーマ バイオロジックス インコーポレイテッド ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
EP1660686B1 (en) * 2003-09-05 2012-05-09 Genencor International, Inc. Hpv cd8+ t-cell epitopes
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
GB0413688D0 (en) 2004-06-18 2004-07-21 Novartis Forschungsstiftung Analysis of methylated nucleic acid
MX2007006120A (es) 2004-11-23 2007-12-07 Adamas Pharmaceuticals Inc Metodo y composicion para administrar a un sujeto un antagonista del receptor de nmda.
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
CN1299769C (zh) 2005-01-31 2007-02-14 中国医学科学院肿瘤医院肿瘤研究所 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
JP4824389B2 (ja) 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
EP2392675A1 (en) 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IFNG gene
CN101646455A (zh) 2007-02-07 2010-02-10 财团法人阪大微生物病研究会 用于癌症的治疗剂
JP5579451B2 (ja) 2007-03-19 2014-08-27 グローブイミューン，インコーポレイテッド ガンのための標的化治療の変異性回避の標的化アブレーションのための組成物
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
EP2071334A1 (en) 2007-12-14 2009-06-17 Transmedi SA Compositions and methods of detecting TIABS
DE102008010954A1 (de) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
ES2840750T3 (es) 2008-09-22 2021-07-07 Baylor College Medicine Métodos y composiciones para generar una respuesta inmune induciendo CD40 y adaptadores del receptor de reconocimiento de patrones
CN101885778B (zh) 2009-05-13 2013-10-16 中国疾病预防控制中心病毒病预防控制所 Hpv16型l2n120e7e6融合蛋白、基因、制备方法及用途
AU2010330364B2 (en) 2009-12-10 2016-05-19 Merck Patent Gmbh Pharmaceutical composition comprising oligopeptides, preferably cilengitide
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2011091319A2 (en) 2010-01-22 2011-07-28 Baylor Research Institute Dendritic cell vaccines
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
PT3023788T (pt) 2010-05-14 2020-05-18 Massachusetts Gen Hospital Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
US20130266659A1 (en) 2010-06-02 2013-10-10 Neil P. Desai Methods of treating bladder cancer
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
GB2487632B (en) 2011-01-14 2014-03-12 Genefirst Ltd Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
EP2478915A1 (en) 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
WO2012118821A2 (en) 2011-02-28 2012-09-07 Indiana University Research And Technology Corporation Glucocorticoid induced leucine zipper mimetics as therapeutic agents in multiple sclerosis
HRP20230443T1 (hr) 2011-05-24 2023-09-15 BioNTech SE Individualizirana cjepiva protiv raka
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
WO2013026027A1 (en) 2011-08-18 2013-02-21 Nestec S.A. Compositions and methods for detecting allelic variants
PT2755997T (pt) 2011-09-15 2018-10-30 Us Health Recetores de célula t que reconhecem mage restrito a hlaa1 ou hla-cw7
WO2013086464A1 (en) 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
US20130210014A1 (en) 2012-02-10 2013-08-15 Jeff Sharman Method for determining the prognosis and therapeutic response in chronic lymphocytic leukemia (cll) patients
AU2013221642A1 (en) 2012-02-15 2014-09-25 Janssen Diagnostics, Llc Highly sensitive method for detecting low frequency mutations
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
RU2018130123A (ru) 2012-05-03 2018-11-07 Фред Хатчинсон Кансэр Рисёч Сентер Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии
KR102702287B1 (ko) 2012-05-15 2024-09-04 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
DK3473707T3 (da) 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
JP2015533473A (ja) 2012-07-12 2015-11-26 ペルシミューン，インコーポレイテッド 個別のがんワクチン及び適応免疫細胞療法
AU2013289970A1 (en) 2012-07-13 2015-01-22 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating CAR T cells
US20150191524A1 (en) 2012-07-27 2015-07-09 The Board Of Trustees Of The University Of Illinoi Engineering t cell receptors
WO2014056986A1 (en) 2012-10-11 2014-04-17 Universitat De Barcelona Method to predict the clinical evolution of a patient suffering of chronic lymphocytic leukemia (cll)
MY175869A (en) 2013-02-26 2020-07-14 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
WO2014150924A2 (en) 2013-03-15 2014-09-25 The Broad Institute, Inc. Accurate typing of hla through exome sequencing
US20160215042A1 (en) 2013-04-19 2016-07-28 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
WO2014184744A1 (en) 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
ES2645393T3 (es) 2013-05-29 2017-12-05 Cellectis Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN
WO2014197369A1 (en) 2013-06-06 2014-12-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
KR102429859B1 (ko) 2013-12-06 2022-08-04 더 브로드 인스티튜트, 인코퍼레이티드 신생물 백신을 위한 제형
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
BR112016016525A2 (pt) 2014-01-17 2017-08-08 Dbv Tech Método para indução de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+ em um indivíduo, método para melhorar uma condição em um indivíduo, e método para a produção de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+
WO2015130968A2 (en) 2014-02-27 2015-09-03 The Broad Institute Inc. T cell balance gene expression, compositions of matters and methods of use thereof
US20170261508A1 (en) 2014-03-14 2017-09-14 The Trustees Of The University Of Pennsylvania Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US20160252511A1 (en) 2014-03-14 2016-09-01 Brian J. Czemiecki Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
DK3152569T3 (da) 2014-06-05 2020-08-17 Aimm Therapeutics Bv Midler og fremgangsmåder til bestemmelse af t-cellegenkendelse
US20170204140A1 (en) 2014-07-23 2017-07-20 Deakin University Antagonistic peptides
RS59710B1 (sr) 2014-08-07 2020-01-31 Pharmassist Ltd Metod određivanja mutacionog statusa pik3ca u uzorku
JP2017525760A (ja) * 2014-08-15 2017-09-07 ジェネクシン・インコーポレイテッドＧｅｎｅｘｉｎｅ， Ｉｎｃ． 子宮頸癌を処置する方法
AU2015341926B2 (en) 2014-11-04 2018-09-27 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
CN107427567A (zh) * 2015-01-29 2017-12-01 宾夕法尼亚大学理事会 检查点抑制剂和疫苗组合物及其用于免疫疗法的用途
EP3265562A4 (en) 2015-03-05 2018-12-19 TrovaGene, Inc. Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids
JP2018512396A (ja) 2015-03-09 2018-05-17 キングス・カレッジ・ロンドン Ｔｈ１応答を増強するためのｒａｒアルファアゴニストを用いた併用療法
EP3075389A1 (en) 2015-03-31 2016-10-05 Technische Universität München T cell receptors and peptides derived by mutations for the treatment of cancer
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
CN107709351A (zh) 2015-06-17 2018-02-16 株式会社医学生物学研究所 细胞毒性t细胞表位肽及其用途
WO2017004153A1 (en) 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
WO2017011710A2 (en) 2015-07-14 2017-01-19 Whitehead Institute For Biomedical Research Chromosome neighborhood structures and methods relating thereto
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017074788A1 (en) 2015-10-27 2017-05-04 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
CN116121281A (zh) 2015-11-27 2023-05-16 卡瑟里克斯私人有限公司 经遗传修饰的细胞及其用途
MX2018009804A (es) 2016-02-12 2018-11-09 Nantomics Llc Identificacion de gran alcance de neoepitopos especificos para pacientes como objetivos terapeuticos para inmunoterapias de cancer.
CN105693828A (zh) 2016-02-17 2016-06-22 深圳市中美康士生物科技有限公司 一种新的eb病毒ebna1表位肽及其在ebv相关疾病的诊断、治疗和预防中的用途
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
US20190307868A1 (en) 2016-03-31 2019-10-10 Neon Therapeutics, Inc. Neoantigens and methods of their use
SG11201808831TA (en) 2016-04-15 2018-11-29 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
IL317855A (en) * 2016-10-26 2025-02-01 Acuitas Therapeutics Inc mRNA vaccines with lipid nanoparticles
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2020000587A1 (zh) 2018-06-26 2020-01-02 龚浩 一种方便清洁的灭虫灯

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544614A (ja) 2006-07-21 2009-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒト内在性レトロウイルスポリペプチド組成物およびその使用法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioinformatics，2016年，Vol. 33, No. 1，pp. 104-111，doi: 10.1093/bioinformatics/btw567
Proc. Nati. Acad. Sci. USA，1992年，Vol. 89，pp. 8058-8062
THE JOURNAL OF BIOLOGICAL CHEMISTRY，2010年，Vol. 285, No. 38，pp. 29608-29622

Also Published As

Publication number Publication date
EP3606550A2 (en) 2020-02-12
JP2023106599A (ja) 2023-08-01
CN118370809A (zh) 2024-07-23
JP2025084910A (ja) 2025-06-03
JP2020515640A (ja) 2020-05-28
CN111093691A (zh) 2020-05-01
WO2018187356A3 (en) 2018-11-01
US20230241207A1 (en) 2023-08-03
WO2018187356A2 (en) 2018-10-11
US12303561B2 (en) 2025-05-20
CA3058807A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
JP7457642B2 (ja) タンパク質抗原およびその使用
JP7491965B2 (ja) ネオ抗原およびその使用方法
EP3810182A1 (en) Neoantigens and uses thereof
WO2021072075A1 (en) Multi-domain protein vaccine
RU2773273C2 (ru) Неоантигены и способы их использования
RU2813924C2 (ru) Неоантигены и их применение
HK40086688A (zh) 新抗原及其使用方法
HK40029579A (en) Protein antigens and uses thereof
HK40004257A (en) Neoantigens and methods of their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240315

R150 Certificate of patent or registration of utility model

Ref document number: 7457642

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150